VEGI Antibodies

Santa Cruz Biotechnology features a diverse variety of VEGI monoclonal antibodies for advanced research in immunology and cell biology. VEGI monoclonal antibodies are compatible with multiple research applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Vascular endothelial growth inhibitor (VEGI) plays a crucial role in regulating angiogenesis and inflammation, making it an important target for studies related to cancer and cardiovascular diseases. By inhibiting the growth of blood vessels, VEGI contributes to the suppression of tumor growth and metastasis, highlighting its significance in therapeutic strategies. Understanding VEGI mechanisms can provide insights into potential treatments for various pathological conditions. VEGI monoclonal antibodies enable researchers to investigate cellular signaling pathways and molecular interactions involved in angiogenesis regulation. Exploring VEGI expression patterns helps identify new therapeutic targets for cancer treatment. Studying VEGI's role in inflammation provides valuable information about immune system responses. Santa Cruz Biotechnology monoclonal antibodies support researchers worldwide in advancing scientific understanding of VEGI's role in human health and disease.